Ergoteles’s PMV Pharmaceuticals PMVP Stock Holding History

Ergoteles’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-257,805	Closed	-$1.23M	–	1408
2023 Q1	$1.23M	Buy	257,805 +234,447	+1,004%	+$1.65M	0.05%	420
2022 Q4	$203K	Buy	+23,358	New	+$249K	0.01%	1073

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ergoteles's PMVP Position: Q2 2023 in Review

Ergoteles sold out of PMV Pharmaceuticals (PMVP) in Q2 2023, closing a stake of 257,805 shares — an estimated $1.23M sold.

Ergoteles first reported a position in PMVP in Q4 2022 and held it in 2 quarters. The position peaked at $1.23M in Q1 2023. 106 funds tracked by Wall St. Rank hold PMVP as of Q2 2023.

Ergoteles reported no remaining PMV Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 257,805 PMV Pharmaceuticals shares in Q2 2023, an estimated $1.23M.
Ergoteles first reported a position in PMV Pharmaceuticals in Q4 2022 and held it in 2 quarters.
Ergoteles's PMV Pharmaceuticals position peaked at $1.23M in Q1 2023.
106 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.